It’s time for In Vivo's 17th annual Deals of the Year contest. We've chosen 12 nominees across three categories – Top M&A, Top Alliance, and Top Financing – and now it’s your turn to pick the winners.

CHARM Therapeutics' CEO discusses its DragonFold technology, applying AI to cancer drug hunting, and the benefits of its Nobel Prize-winning roots.

One month after announcing a pipeline pivot, Ovid Therapeutics talked to In Vivo about the importance of making strategic decisions with discipline, and the imminent neurology revolution.

Glen Clova Scientific is galvanizing virus-like particle technology with disruptive advances in manufacturing to treat immune-related dermatology conditions in often overlooked senile populations.

As pharmaceutical companies face a crowded and competitive landscape, the debate between being first-in-class or best-in-class is evergreen. This strategic choice impacts new product launches, with first-to-market therapies offering market share and brand recognition advantages, while best-in-class options can capture value through product differentiation and commercial execution. In Vivo talked to L.E.K. Consulting on how to make a product stand out from the crowd.

Data provided by Biomedtracker show that data-driven methodologies within R&D are propelling life sciences to unprecedented advancements. It is making drug development faster, more efficient and more personalized.